Disease Burden, Clinical Management, and Unmet Treatment Need of Patients With Moderate to Severe Alopecia Areata: Consensus Statements, Insights, and Practices From CERTAAE Delphi Panel

    April 2024 in “ Frontiers in medicine
    Lidia Rudnicka, Magdalena Trzeciak, Erkan Alpsoy, Petr Arenberger, Sibel Alper, Nina Benáková, Svetlana Bobko, Murat Borlu, Magdalena Czarnecka Operacz, Burhan Engın, Tülin Ergun, İlgen Ertam, Olga Filipovská, Aida Gadzhigoroeva, Martina Kojanová, Aleksandra Lesiak, А. В. Миченко, Nikolay N. Murashkin, Nahide Onsun, Witold Owczarek, Zuzana Plzáková, Adam Reich, Marie Selerová, Burcu Gürbüz
    Image of study
    TLDR Alopecia Areata significantly lowers quality of life and current treatments are inadequate, highlighting a need for better therapies and standardized treatment protocols.
    The study, involving a 2-round Delphi panel with 23 dermatologists from Russia, Türkiye, Poland, and Czechia, aimed to understand the burden and management of moderate-to-severe Alopecia Areata (AA) in these countries. It concluded that AA significantly affects the quality of life (QoL) of patients and their families, especially when lesions appear in visible areas other than the scalp, leading to higher work and productivity impairment in adults. The consensus among dermatologists was that skin biopsies and trichoscopy are important for diagnosis, but there is a need for better severity scoring systems. Current treatments like topical therapies, corticosteroids, and systemic immune modifiers were found to be insufficient, indicating a substantial unmet medical need. The study calls for access to novel treatments and more research to develop effective therapies with acceptable safety profiles, aligning with global research on the psychosocial impact of AA and the necessity for standardized treatment protocols.
    Discuss this study in the Community →

    Research cited in this study

    19 / 19 results

    Related Community Posts Join

    6 / 1000+ results

      community Binding affinity of pyrilutamide!

      in Update  172 upvotes 2 years ago
      Pyrilutamide, a nonsteroidal antiandrogen drug under development for the potential treatment of androgenic alopecia. The conversation discusses its binding affinity to the androgen receptor and the timeline for possible availability after trials are completed in the United States and China.

      community No gains after 4 years of min and fin

      in Progress Pictures  92 upvotes 3 months ago
      User has seen no improvement after 4 years of using minoxidil and finasteride, and recently started dutasteride. Suggestions include adding oral minoxidil, microneedling, and considering a hair transplant.

      community Unofficial Dermapen/Roller Guide

      in Treatment  252 upvotes 5 years ago
      Treatments for hair loss, including microneedling (dermarolling and dermapen) and the use of minoxidil, finasteride, and RU58841. It provides detailed information about cost and usage of the various treatments, as well as potential side effects.

      community Hair Remedies that Don't Work for Anybody Seeking Hair Regrowth

      in Treatment  7 upvotes 4 years ago
      Hair loss treatments discussed include minoxidil, finasteride, and RU58841. Salon products and supplements generally don't work for hair regrowth unless there's a severe nutritional deficiency, while hormonal treatments like estrogen and spironolactone can be effective.

    Similar Research

    5 / 1000+ results